IJCEMR

Article http://dx.doi.org/10.26855/ijcemr.2023.01.013

T-lymphocyte Subsets Assessment of the Efficacy of PD-L1 Inhibitors in Combination with Chemotherapy in the First-line Treatment of Elderly with Extensive-stage Small Cell Lung Cancer

Download PDF How to cite this paper

TOTAL VIEWS: 5368

Zhaoxue Lu^1,3,*, Ying Li^2,3, Xuguang Zhang^2,3

¹Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.

²Department of Radiation Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, China.

³First Clinical College, Xuzhou Medicine University, Xuzhou, Jiangsu, China.

*Corresponding author: Zhaoxue Lu

Published: February 6,2023

Abstract

Objective: To investigate the clinical efficacy of PD-L1 inhibitor combined with chemotherapy in the treatment of elderly extensive-stage small cell lung cancer and the changes of T lymphocyte subsets before and after treatment. Methods: Sixty-four elderly patients admitted to the Affiliated Hospital of Xuzhou Medical University from September 2020 to May 2022 who met the inclusion criteria for primary diagnosis of extensive-stage small cell lung cancer were selected, 34 patients in the control group and 30 patients in the observation group. All patients in the control group were given platinum-based etoposide regimen chemotherapy, while patients in the observation group were treated with dulvalizumab or atelelizumab combined with platinum-etoposide. The tumor markers, lymphocyte subsets, progression-free survival and depth of remission were compared between the two groups after 4 courses of treatment. Results: The CD3+, CD4+ and CD4+/CD8+ T lymphocyte ratios in the observation group were significantly higher than those in the control group, with statistically significant differences (P< 0.05) while there was no significant difference between the two CD8+ groups after treatment, (P> 0.05). Progression-free survival (7.5 months vs. 5.9 months, P = 0. 013), the depth of remission in the observation group was better than that in the control group. Conclusion: PD-L1 inhibitor combined with chemotherapy for distant metastatic small cell lung cancer effectively modulates T-lymphocyte subpopulation, improves the body's immune capacity, and achieves better survival benefit.

Keywords

T-lymphocyte subsets, extensive-stage small cell lung cancer, PD-L1 inhibitors, chemotherapy

References

[1] Siegel, R.L., et al., Cancer statistics, 2022. CA Cancer J Clin, 2022. 72(1): p. 7-33.

[2] Govindan, R., et al., Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 2006. 24(28): p. 4539-44.

[3] Zelen, M., Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3, 1973. 4(2): p. 31-42.

[4] Kalemkerian, G.P., Small Cell Lung Cancer. Semin Respir Crit Care Med, 2016. 37(5): p. 783-796.

[5] Mansfield, A.S., et al., Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol, 2020. 31(2): p. 310-317.

[6] Paz-Ares, L., et al., Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 2019. 394(10212): p. 1929-1939.

[7] Nishino, M., et al., Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol, 2017. 14(11): p. 655-668.

[8] Rathore, A.S., et al., CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res, 2014. 140(3): p. 361-9.

[9] Chen, Y., et al., Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer. Cancer Immunol Immunother, 2021. 70(10): p. 2867-2876.

[10] Sun, C., et al., Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer. Onco Targets Ther, 2020. 13: p. 6475-6483.

[11] Kamphorst, A.O., et al., Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A, 2017. 114(19): p. 4993-4998.

[12] Huang, A.C., et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017. 545(7652): p. 60-65.

[13] Miao, K., et al., Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol, 2022. 13: p. 912180.

How to cite this paper

T-lymphocyte Subsets Assessment of the Efficacy of PD-L1 Inhibitors in Combination with Chemotherapy in the First-line Treatment of Elderly with Extensive-stage Small Cell Lung Cancer

How to cite this paper: Zhaoxue Lu, Ying Li, Xuguang Zhang. (2023) T-lymphocyte Subsets Assessment of the Efficacy of PD-L1 Inhibitors in Combination with Chemotherapy in the First-line Treatment of Elderly with Extensive-stage Small Cell Lung Cancer. International Journal of Clinical and Experimental Medicine Research, 7(1), 73-77.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.01.013